AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ENDRA Life Sciences Inc. Director's Dealing 2026

Jan 23, 2026

35444_dirs_2026-01-23_a40cf751-2faf-4076-9026-cb863af50a6e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ENDRA Life Sciences Inc. (NDRA)
CIK: 0001681682
Period of Report: 2026-01-21

Reporting Person: DIGIANDOMENICO ANTHONY (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-01-21	Common Stock	A	60324	—	Acquired	136589	Direct

Footnotes

F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2027.

F2: Includes unvested RSUs.